Journal of Clinical Oncology
Articles in this Issue
Self-assembled patient-derived tumor-like cell clusters for personalized drug testing in diverse sarcomas.
11569 Background: Soft tissue sarcomas (STS) are rare malignancies with over 100 distinct histological subtypes. Their rarity and heterogeneity pose signi...
Seizure-related homolog 6 (SEZ6) expression and ctDNA methylation profiles in patients with high-grade neuroendocrine carcinomas (NECs)/neuroendocrine tumors (NETs) from a phase 1 study of ABBV-706 in advanced solid tumors.
3085 Background: SEZ6 is a transmembrane protein with overexpression in small cell lung cancer (SCLC) and other neuroendoc...
KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).
TPS4209 Background: There is a substantial need for more effective and tolerable first-line treatment options for patients with advanced ESCC. B7-H3 is a...
Integrated supportive and nutrition care program for older adults with advanced pancreatic cancer: A feasibility study.
e24050 Background: Pancreatic cancer is an aggressive malignancy that disproportionately impacts older adults. Older adults with pancreatic cancer experie...
Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a "cold" ovarian tumor model.
2538 Background: We previously discovered that bone marrow derived Mesenchymal stromal cells (BM-MSCs) migrate to the stroma of numerous cancers and their...
Association of plasma biomarkers with diagnostic molecular markers for potential diagnosis and prognosis of diffuse gliomas.
2045 Background: Diffuse gliomas were recently reclassified based on the 2021 WHO Classification criteria. Several molecular changes which carry diagnosti...
Association of cognitive factors with lung cancer risk in the UK Biobank cohort.
e23006 Background: Previous studies suggest that cognitive reserve, encompassing factors like education, occupation, and physical activity, may influence...
Factors associated with receipt of surveillance breast MRI among racially/ethnically diverse women with a personal history of breast cancer.
1584 Background: Surveillance breast imaging among breast cancer (BC) survivors is recommended for early detection of local recurrence or contralateral BC...
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.
TPS1131 Background: Endocrine therapy(ET) resistance is a major challenge in treating estrogen receptor-positive (ER+), hu...
Identifying delivery of palliative care in administrative billing claims data: A scoping review.
e23128 Background: Palliative care is increasingly recognized as an essential component of whole-person healthcare for people living with serious illnesse...
Beyond survival: Prospective longitudinal insights into quality of life after hepatectomy for colorectal liver metastases.
11122 Background: The long-term health related quality of life (QoL) after curative intent hepatectomy for high-risk colorectal liver metastases (CRLM) is...
Experience and safety of chemotherapy and immunotherapy in patients with small cell lung cancer.
e20132 Background: The majority of patients (Pts) diagnosed with small cell lung cancer (SCLC) present with advanced-stage disease at diagnosis, therefore...
The phase 1 clinical trial of anti–PD-1 ab plus intrahepatic injection of oncolytic virus (OH2) combined radiotherapy of liver metastasis in stage IV melanoma.
9547 Background: Patients with melanoma and liver metastases generally exhibit reduced responses to systemic immunotherapy. Oncolytic herpes simplex virus...
Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
6055 Background: CUE-101 is a novel fusion protein designed to selectively engage and expand HPV16-specific T-cells to promote an anti-tumor immune respon...
Demographic and socioeconomic factors of follicular thyroid carcinoma.
e18125 Background: Follicular thyroid carcinoma (FTC) is an atypical malignancy that develops within the follicular cells of the thyroid. One study found...
Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.
4505 Background: First-line nivolumab plus ipilimumab (NIVO+IPI) provided substantial long-term survival benefits over sun...
Lurbinectedin for small cell lung cancer (SCLC): Response patterns and survival outcomes by line of therapy.
e20128 Background: Small cell lung cancer (SCLC) remains a therapeutic challenge with limited treatment options and poor survival outcomes. Lurbinectedin...
Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison.
e15550 Background: Fruquintinib (fru), regorafenib (reg), and trifluridine/tipiracil (TAS102) are 3 rd line treatments for patient...
Molecular characterization of STEAP1 and -2 in advanced prostate cancer.
5072 Background: STEAP 1 and 2 (six-transmembrane epithelial antigen of prostate) are metalloreductase proteins involved in a variety of biolo...
A phase 3, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician’s choice in participants with triple-negative breast cancer who received neoadjuvant therapy and did not achieve a pathologic complete response at surgery.
TPS616 Background: Trophoblast cell surface antigen 2 (TROP2) expression is higher in triple-negative breast cancer (TNBC) vs other breast cancer subtypes...
Clinical features and survival outcomes of small, node negative breast cancer: A multicenter, retrospective study.
e12554 Background: Early-stage breast cancer (T1N0M0 BC) generally has a favorable prognosis, but relapse risks persist over time. The role of adjuvant sy...
Identifying barriers and effective strategies to improve biomarker testing rates in non-small cell lung cancer.
e23226 Background: Biomarker testing plays a pivotal role in the management of non-small cell lung cancer (NSCLC). However, despite advancements in diagno...
Lobaplatin-based chemotherapy with immunotherapy as first-line treatment in patients with advanced NSCLC: A real-world bidirectional cohort study.
e20573 Background: Lobaplatin (LBP), a third-generation platinum-based antitumor drug, exhibits strong anti-cancer activity and low toxicity, without cros...
Prognostic value of baseline and dynamic circulating tumor cell monitoring in advanced lung cancer patients receiving immunotherapy.
8532 Background: Circulating tumor cells (CTCs) and PD-L1 expression on CTCs (bPD-L1) are emerging biomarkers for predicting immunotherapy response. This...
Successful implementation of virtual oncology and hematology services in a rural health system.
e13887 Background: Oncology and Hematology patients in rural areas lack access to specialty care. We report a successful implementation of a virtual care...